Progress Bifurcation Global Registry
Launched by MINNEAPOLIS HEART INSTITUTE FOUNDATION · Oct 20, 2021
Trial Information
Current as of June 01, 2025
Recruiting
Keywords
ClinConnect Summary
The Progress Bifurcation Global Registry is a study focused on understanding how to best treat blockages in arteries, specifically where a main artery splits into smaller branches. These blockages, known as coronary bifurcation lesions, can be challenging to treat effectively. The study aims to gather information from multiple medical centers about the different methods used to treat these blockages and the results of those treatments. By doing this, researchers hope to learn more about how often these procedures are performed, which techniques are most effective, and what outcomes patients experience.
To participate in this study, individuals must be over 18 years old and undergoing a specific heart procedure called percutaneous coronary intervention (PCI) for a bifurcation lesion. Participants will be part of an observational registry, meaning their treatment and outcomes will be recorded and analyzed, but they will not be receiving a new treatment or medication as part of the study. This research will help improve future treatment strategies for patients with similar heart conditions.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Over 18 years of age
- • undergoing bifurcation percutaneous coronary intervention
About Minneapolis Heart Institute Foundation
The Minneapolis Heart Institute Foundation is a leading medical research organization dedicated to advancing cardiovascular care through innovative clinical trials and research initiatives. Committed to improving patient outcomes, the foundation collaborates with healthcare professionals, academic institutions, and industry partners to explore cutting-edge therapies and interventions for heart disease. With a strong emphasis on evidence-based medicine and patient-centered research, the Minneapolis Heart Institute Foundation strives to translate scientific discoveries into practical solutions that enhance the quality of life for individuals with cardiovascular conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Minneapolis, Minnesota, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials